Vol 28, No 6 (2017)

The paper analyzes the possibilities of effective primary, secondary (screenings) and tertiary prevention in a population aged over 65 years and at the individual level. It describes the Crystal risk assessment model created according to the results of epidemiological studies in Russia.

Myasthenia is a severe disease that results from an antibody-mediated autoimmune disorder of neuromuscular synaptic transmission. The high prevalence of the disease, the severity of its clinical manifestations, and the instability of the patients’ status even during therapy determine the urgency to elaborate optimal therapeutic strategies for the management of these patients. The paper presents current approaches to treating myasthenia, describes in detail drug treatment options and the possibility of surgical intervention, and gives data on the use of ozone therapy for this disease.

Cognitive impairment (CI) is one of the most common disorders among elderly and senile people. The prevalence of all CIs no dementia in people aged over 80 years is as high as 40 to 80% according to some data. The paper gives an algorithm for the diagnosis of CI and for the management of these patients.

The article presents the review data to identify risks of development of cognitive deficit in patients of senior age groups with coronary heart disease, which shows coronary artery bypass grafting. We presents the latest research on biomarkers of cognitive impairment, and the innovation of ways of correction of the cognitive deficit in these patients.

The paper presents a correlation analysis of biological markers for aging in combat veterans. Data on psychosocial, clinical, laboratory, and functional parameters of the body are used. Knowing some parameters of homeostasis and the indicators of cardiovascular system functioning, the rate of aging can be determined using the given formulas.

The paper presents information on triple antihypertensive therapy for hypertension and gives the results indicating its higher efficiency, safety in the use of amlodipine, indapamide, and perindopril.

Flupirtine is a promising agent for the relief of pain of various origin. It has analgesic, muscle relaxant, and neuroprotective activities. The pharmacological properties of flupirtine allow it to be effectively used to treat low back pain, especially in patients with comorbidity. The analgesic activity and tolerability of flupirtine in the therapy of acute nonspecific low back pain in patients with comorbidity.

The therapeutic environment for elderly patients with cognitive impairment should be understandable and safe and should mould a sense of demand, interest, and permanent employment, which is aimed at maintaining and compensating for mental disorders.

Measurement of heart rate variability is an available technique for assessing the autonomic regulation of cardiac activity. In elderly patients with coronary heart disease, cardiac autonomic imbalance with sympathetic predominance due to reduced vagal tone is concurrent with both a history of myocardial infarction and with unstable angina.

The article highlights the results of studies on the interaction of cognitive deficit and syndrome malnutrition in patients of older age groups with arterial hypertension. We described the analysis of the geriatric status and proposed rehabilitation treatment measures for comprehensive management of such patients.

The article describes the main types of cognitive impairment encountered in the practice of a specialist of anti-ageing medicine, in particular, orthorexia nervosa, dismorphomania and body dysmorphic disorder. The questions of pathogenesis, early diagnosis. We offered modern ways of correction of cognitive disorders.

The results of studying the health status and lifestyle of a female centenarian living in Yakutia reveal the secrets of her longevity.

Mucopolysaccharidosis type 1 (MPS 1) is included by the Ministry of Health of the Russian Federation in the list of 700 orphan diseases. The etiopathogenesis of MPS 1 is caused by mutations in the structural gene for the lysosomal enzyme а-L-iduronidase (IDUA), which is the reason for the accumulation of products of incomplete glycosaminoglycan (GAG) disintegration in the cell lysosomes. The mutations are inherited in an autosomal recessive pattern. There are currently more than 100 known mutations in the IDUA gene. Different mutations cause different clinical forms of MPS 1, such as Hurler, Hurler-Sheie, and Sheie syndromes. The polymorphism of clinical manifestations and the low incidence of MPS 1 impede its timely diagnosis and, accordingly, early initiation of therapy. The diagnosis of MPS 1 is based on the identification of the specific phenotype of patients, the determination of the urinary excretion of GAGs and their fractions, tandem mass spectrometry, and DNA diagnosis. Enzyme replacement therapy and bone marrow transplantation improve the follow-up of patients with MPS 1.